In vivo experiments verified that leonurine inhibited CML xenograft growth by repressing miR-18a-5p/SOCS5/JAK2/STAT3, suggesting a potential approach to CML therapy. The gene discussed is SOCS5; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.